GSK the market absolutely hates this deal for GSK down 8% as I type. It's no secret they plan to re-enter the oncology space and have a good chance to add a second product w their BCMA ADC. I have no position in GSK but I may look to start one. They do have a lot of debt but most of this deal can be paid for once they close the sale of their nutrition business
Akeega is a fixed-dose combination of Zytiga and Zejula (the PARP inhibitor from GSK/Tesaro). JNJ’s licensed the commercial rights to Zejula in prostate cancer from Tesaro in 2016.
Akeega can be considered a lifecycle management maneuver by JNJ insofar as Zytiga will soon be off-patent.